WO2021184115A1 - Use of bucillamine in the treatment of infectious diseases - Google Patents

Use of bucillamine in the treatment of infectious diseases Download PDF

Info

Publication number
WO2021184115A1
WO2021184115A1 PCT/CA2021/050350 CA2021050350W WO2021184115A1 WO 2021184115 A1 WO2021184115 A1 WO 2021184115A1 CA 2021050350 W CA2021050350 W CA 2021050350W WO 2021184115 A1 WO2021184115 A1 WO 2021184115A1
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutically effective
effective amount
bucillamine
per day
infectious disease
Prior art date
Application number
PCT/CA2021/050350
Other languages
French (fr)
Inventor
Fabio Andrea CHIANELLI
Michael Frank
Original Assignee
Revive Therapeutics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revive Therapeutics Ltd. filed Critical Revive Therapeutics Ltd.
Priority to US17/912,597 priority Critical patent/US20230172884A1/en
Priority to CA3172170A priority patent/CA3172170A1/en
Priority to JP2022556099A priority patent/JP2023518430A/en
Priority to KR1020227036230A priority patent/KR20230015320A/en
Priority to EP21772039.0A priority patent/EP4121035A4/en
Publication of WO2021184115A1 publication Critical patent/WO2021184115A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Definitions

  • the present invention relates to pharmaceutical compositions comprising bucillamine and their use for the treatment of infectious diseases.
  • NAC works to prevent acute lung injury caused by influenza virus infection through inhibition of these ROS-mediated mechanisms. 4 ⁇ 7 NAC has been investigated clinically and found to significantly attenuate clinical symptoms associated with influenza infection, especially in elderly at-risk patients. 5 While NAC is easily taken up by cells and has low toxicity, clinical efficacy has required long-term and high-dose administration because of modest relative potency, limiting its clinical applicability.
  • Bucillamine N-(mercapto-2-methylpropionyl)-l-cysteine is a cysteine derivative with 2 thiol groups.
  • the structure of bucillamine is:
  • Bucillamine provides protection against oxidative stress by donating thiol groups to GSH. This reactivates GSH and increases the amount available to remove reactive oxygen species, enhancing its endogenous antioxidant activity.
  • the present inventors hypthesized that Bucillamine can be used to treat infectious disease symptoms, such as influenza symptoms and coronavirus disease 2019 (COVID 19) symptoms, by reducing tissue damage from reactive oxygen species.
  • the present disclosure in one aspect, relates to a method for the treatment of an infectious disease in a mammal comprising administering a therapeutically effective amount of bucillamine or a pharmaceutically acceptable salt or solvate thereof, to a mammal in need thereof.
  • the infectious disease is influenza.
  • the infectious disease is coronavirus disease 2019.
  • the method of treatment is for preventing or reducing acute lung injury during an infection.
  • pharmaceutically acceptable compositions of the present disclosure can be administered to humans and other animals at a unit dose within range of about 10 mg to about 50 mg, the range of 100 mg to about 200 mg, 100mg, and 200 mg and this should provide a therapeutically effective dose.
  • the daily dose is 300 mg per day. In another aspect, the daily does is 600 mg per day. In certain aspects, the unit dose may be higher than 200 mg. In another aspect, the daily dose is 600 mg per day. In certain aspects, the unit dose may be 200 mg to 300 mg. In certain other aspects, the daily dose may be higher than 600 mg per day. In another aspect, the daily dose is 600 mg to 800 mg per day. In another aspect, the daily dose is up to 1000 mg per day.
  • the daily dose is up to 1500 mg per day, up to 2000 mg per day, up to 2500 mg per day, up to 3000 mg per day, 300-600 mg per day, 300-1000 mg per day, 300-1500 mg per day, 300-2000 mg per day, 300-2500 mg per day, 300-3000 mg per day, 600- 1000 mg per day, 600-1500 mg per day, 600-2000 mg per day, 600-2500 mg per day, 600-3000 mg per day.
  • the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly, the optimum dosage may be determined by the practitioner who is treating any particular patient.
  • the present disclosure in another aspect, relates to a use of a pharmaceutical composition including bucillamine or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers, diluents and excipients for the treatment of an infectious disease.
  • the infectious disease is influenza.
  • the infectious disease is coronavirus disease 2019.
  • the use is for preventing or reducing acute lung injury during an infection.
  • pharmaceutically acceptable compositions of the present disclosure can be used at a unit dose within range of about 10 mg to about 50 mg, the range of 100 mg to about 200 mg, 100mg, and 200 mg and this should provide a therapeutically effective dose.
  • the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly, the optimum dosage may be determined by the practitioner who is treating any particular patient. DETAILED DESCRIPTION
  • a therapeutically effective amount of the bucillamine or pharmaceutically acceptable salts or solvates thereof may be presented as a pharmaceutical composition.
  • the invention provides a pharmaceutical composition of bucillamine or pharmaceutically acceptable salts or solvates thereof in admixture with one or more pharmaceutically acceptable carriers, diluents, or excipients.
  • the carrier(s), diluent(s) or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • compositions of the present invention including bucillamine may be in the form of and/or may be administered as a pharmaceutically acceptable salt.
  • a pharmaceutically acceptable salt may be readily prepared by using a desired acid or base as appropriate.
  • the salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
  • Suitable addition salts are formed from acids which form non-toxic salts and examples are hydrochloride, hydrobromide, hydroiodide, sulphate, nitrate, phosphate, hydrogen phosphate, dihydrogen phosphate acetate, maleate, malate, fumarate, lactate, tartrate, citrate, formate, gluconate, succinate, pyruvate, oxalate, oxaloacetate, trifluoroacetate, saccharinate, benzoate, methanesulphonate, ethanesulphonate, benzenesulphonate, p-toluenesulphonate and isethionate.
  • Suitable salts may also be formed from bases, forming salts including ammonium salts, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium.
  • Pharmaceutically acceptable salts may also be prepared from other salts, including other pharmaceutically acceptable salts, using conventional methods.
  • Those skilled in the art of organic or coordination chemistry will appreciate that many organic and coordination compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as “solvates”.
  • solvates For example, a complex with water is known as a “hydrate”. Solvates of bucillamine are within the scope of the present invention.
  • compositions of the invention may be formulated for administration by any appropriate route, for example by the oral (including buccal or sublingual). Therefore, the pharmaceutical compositions of the invention may be formulated, for example, as tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral solutions or suspensions. Such pharmaceutical formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s).
  • Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatine, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatine, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan, monooleate, or acacia; non- aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and, if desired, conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, methyl cellulose, glucose syrup, gelatine, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan, mono
  • compositions of the present invention may be suitable for the treatment of diseases in a human or animal patient.
  • the patient is a mammal including a human, horse, dog, cat, sheep, cow, or primate.
  • the patient is a human.
  • the patient is not a human.
  • the term “effective amount” means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.
  • therapeutically effective amount means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder.
  • the term also includes within its scope amounts effective to enhance normal physiological function.
  • treatment refers to defending against or inhibiting a symptom, treating a symptom, delaying the appearance of a symptom, reducing the severity of the development of a symptom, and/or reducing the number or type of symptoms suffered by an individual, as compared to not administering a pharmaceutical composition of the invention.
  • treatment encompasses the use in a palliative setting
  • the present invention in one embodiment, relates to a method for the treatment of an infectious disease in a mammal comprising administering a therapeutically effective amount of bucillamine or a pharmaceutically acceptable salt or solvate thereof, to a mammal in need thereof.
  • the infectious disease is influenza.
  • the infectious disease is coronavirus disease 2019.
  • the primary objective is to compare the frequency of hospitalization or death in patients with mild-moderate COVID-19 receiving Bucillamine therapy with those receiving placebo.
  • the primary endpoint is the proportion of patients meeting a composite endpoint of hospitalization or death from the time of the first dose through Day 28 following randomization.
  • Efficacy was assessed by comparing clinical outcomes (death or hospitalization), disease severity using the 8-category NIAID COVID ordinal scale, supplemental oxygen use, and progression of COVID-19 between patients receiving standard-of-care plus Bucillamine (high dose and/or low dose) and patients receiving standard-of-care plus placebo. Preliminary indications are that none of the patients receiving Bucillamine in the trial have to date been hospitalised for COVID-19 or have died from COVID-19.
  • the present invention in another embodiment, relates to a use of a pharmaceutical composition including bucillamine or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers, diluents and excipients for the treatment of an infectious disease.
  • infectious disease is influenza.
  • infectious disease is coronavirus disease.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Methods and uses for the treatment or prevention of an infectious disease in a mammal including in a human, including administering a therapeutically effective amount of bucillamine or a pharmaceutically acceptable salt or solvate thereof to a mammal in need thereof. The infectious disease can include influenza. The infectious disease can also include coronavirus disease 2019.

Description

USE OF BUCILLAMINE IN THE TREATMENT OF INFECTIOUS DISEASES
FIELD
The present invention relates to pharmaceutical compositions comprising bucillamine and their use for the treatment of infectious diseases.
BACKGROUND
Current antiviral interventions for influenza have exhibited modest efficacy, especially in improving mortality in at-risk populations, such as the elderly.1 ·2 Novel antivirals have been plagued by poor oral bioavailability and lack of efficacy when not delivered early.1 This is because these drugs mostly act to prevent the early processes of virus binding to cells or viral replication.2 Thiols, particularly N-acetylcysteine (NAC), with antioxidant and reducing activity have been investigated as effective therapies that abrogate the potential for influenza to cause severe disease.3·4·5 Restoration of glutathione, the major intracellular thiol antioxidant, is a critical functional activity of NAC.6 Reactive oxygen species (ROS) generation during influenza virus infection aggravate destructive inflammation and programmed death of epithelial cells.7 Studies in human cells and animal models have shown that NAC works to prevent acute lung injury caused by influenza virus infection through inhibition of these ROS-mediated mechanisms.4·7 NAC has been investigated clinically and found to significantly attenuate clinical symptoms associated with influenza infection, especially in elderly at-risk patients.5 While NAC is easily taken up by cells and has low toxicity, clinical efficacy has required long-term and high-dose administration because of modest relative potency, limiting its clinical applicability.
When an immune response is triggered by an Influenza virus, this results in the accumulation of cells which secrete a variety of toxic chemicals, such as reactive oxygen species. These chemicals are intended to kill infected cells, but they can also damage surrounding healthy tissue and themselves cause some of the symptoms associated with Influenza.
Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.
SUMMARY OF THE INVENTION
Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) is a cysteine derivative with 2 thiol groups. The structure of bucillamine is:
Figure imgf000003_0001
This compound has also been shown to prevent oxidative and reperfusion injury in heart and liver tissues.8 Bucillamine is non-toxic with proven safety and activity as a clinically approved IND therapeutic intervention for cystinuria and rheumatoid arthritis and is highly cell permeable for efficient delivery into cells.8·9 Bucillamine is 16-fold more potent than NAC as a thiol donor in vivo, giving it vastly superior function in restoring glutathione.
Bucillamine provides protection against oxidative stress by donating thiol groups to GSH. This reactivates GSH and increases the amount available to remove reactive oxygen species, enhancing its endogenous antioxidant activity. The present inventors hypthesized that Bucillamine can be used to treat infectious disease symptoms, such as influenza symptoms and coronavirus disease 2019 (COVID 19) symptoms, by reducing tissue damage from reactive oxygen species.
The present disclosure, in one aspect, relates to a method for the treatment of an infectious disease in a mammal comprising administering a therapeutically effective amount of bucillamine or a pharmaceutically acceptable salt or solvate thereof, to a mammal in need thereof. In one aspect, the infectious disease is influenza. In another aspect, the infectious disease is coronavirus disease 2019. In a further aspect, the method of treatment is for preventing or reducing acute lung injury during an infection. In certain aspects of methods of the present disclosure, pharmaceutically acceptable compositions of the present disclosure can be administered to humans and other animals at a unit dose within range of about 10 mg to about 50 mg, the range of 100 mg to about 200 mg, 100mg, and 200 mg and this should provide a therapeutically effective dose. In another aspect, the daily dose is 300 mg per day. In another aspect, the daily does is 600 mg per day. In certain aspects, the unit dose may be higher than 200 mg. In another aspect, the daily dose is 600 mg per day. In certain aspects, the unit dose may be 200 mg to 300 mg. In certain other aspects, the daily dose may be higher than 600 mg per day. In another aspect, the daily dose is 600 mg to 800 mg per day. In another aspect, the daily dose is up to 1000 mg per day. In other aspects, the daily dose is up to 1500 mg per day, up to 2000 mg per day, up to 2500 mg per day, up to 3000 mg per day, 300-600 mg per day, 300-1000 mg per day, 300-1500 mg per day, 300-2000 mg per day, 300-2500 mg per day, 300-3000 mg per day, 600- 1000 mg per day, 600-1500 mg per day, 600-2000 mg per day, 600-2500 mg per day, 600-3000 mg per day. However, the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly, the optimum dosage may be determined by the practitioner who is treating any particular patient.
The present disclosure, in another aspect, relates to a use of a pharmaceutical composition including bucillamine or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers, diluents and excipients for the treatment of an infectious disease. In another aspect, the infectious disease is influenza. In another aspect, the infectious disease is coronavirus disease 2019. In another aspect, the use is for preventing or reducing acute lung injury during an infection. In certain aspects of uses of the present disclosure, pharmaceutically acceptable compositions of the present disclosure can be used at a unit dose within range of about 10 mg to about 50 mg, the range of 100 mg to about 200 mg, 100mg, and 200 mg and this should provide a therapeutically effective dose. However, the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly, the optimum dosage may be determined by the practitioner who is treating any particular patient. DETAILED DESCRIPTION
Throughout this specification the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
For use in therapy a therapeutically effective amount of the bucillamine or pharmaceutically acceptable salts or solvates thereof, may be presented as a pharmaceutical composition. Thus, in a further embodiment the invention provides a pharmaceutical composition of bucillamine or pharmaceutically acceptable salts or solvates thereof in admixture with one or more pharmaceutically acceptable carriers, diluents, or excipients. The carrier(s), diluent(s) or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
When applicable, the compositions of the present invention, including bucillamine may be in the form of and/or may be administered as a pharmaceutically acceptable salt.
Typically, a pharmaceutically acceptable salt may be readily prepared by using a desired acid or base as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
Suitable addition salts are formed from acids which form non-toxic salts and examples are hydrochloride, hydrobromide, hydroiodide, sulphate, nitrate, phosphate, hydrogen phosphate, dihydrogen phosphate acetate, maleate, malate, fumarate, lactate, tartrate, citrate, formate, gluconate, succinate, pyruvate, oxalate, oxaloacetate, trifluoroacetate, saccharinate, benzoate, methanesulphonate, ethanesulphonate, benzenesulphonate, p-toluenesulphonate and isethionate.
Suitable salts may also be formed from bases, forming salts including ammonium salts, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium.
Pharmaceutically acceptable salts may also be prepared from other salts, including other pharmaceutically acceptable salts, using conventional methods. Those skilled in the art of organic or coordination chemistry will appreciate that many organic and coordination compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as “solvates”. For example, a complex with water is known as a “hydrate”. Solvates of bucillamine are within the scope of the present invention.
Pharmaceutical compositions of the invention may be formulated for administration by any appropriate route, for example by the oral (including buccal or sublingual). Therefore, the pharmaceutical compositions of the invention may be formulated, for example, as tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral solutions or suspensions. Such pharmaceutical formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s).
Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatine, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatine, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan, monooleate, or acacia; non- aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and, if desired, conventional flavouring or colouring agents. It should be understood that in addition to the ingredients particularly mentioned above, the formulations may include other agents conventional in the art having regard to the type of formulation in question.
The compositions of the present invention may be suitable for the treatment of diseases in a human or animal patient. In one embodiment, the patient is a mammal including a human, horse, dog, cat, sheep, cow, or primate. In one embodiment the patient is a human. In a further embodiment, the patient is not a human.
As used herein, the term “effective amount” means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician. Furthermore, the term “therapeutically effective amount” means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function.
As used herein the term “treatment” refers to defending against or inhibiting a symptom, treating a symptom, delaying the appearance of a symptom, reducing the severity of the development of a symptom, and/or reducing the number or type of symptoms suffered by an individual, as compared to not administering a pharmaceutical composition of the invention. The term treatment encompasses the use in a palliative setting
Accordingly, the present invention, in one embodiment, relates to a method for the treatment of an infectious disease in a mammal comprising administering a therapeutically effective amount of bucillamine or a pharmaceutically acceptable salt or solvate thereof, to a mammal in need thereof. In another aspect, the infectious disease is influenza. In another aspect, the infectious disease is coronavirus disease 2019.
Clinical Trial
A Phase 3 confirmatory clinical trial titled, “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients with Mild-Moderate COVID-19”, was undertaken to enroll up to 1 ,000 patients randomized 1 :1 :1 to receive Bucillamine 100 mg three times a day (“TID”), Bucillamine 200 mg TID or placebo TID for up to 14 days. The primary objective is to compare the frequency of hospitalization or death in patients with mild-moderate COVID-19 receiving Bucillamine therapy with those receiving placebo. The primary endpoint is the proportion of patients meeting a composite endpoint of hospitalization or death from the time of the first dose through Day 28 following randomization. Efficacy was assessed by comparing clinical outcomes (death or hospitalization), disease severity using the 8-category NIAID COVID ordinal scale, supplemental oxygen use, and progression of COVID-19 between patients receiving standard-of-care plus Bucillamine (high dose and/or low dose) and patients receiving standard-of-care plus placebo. Preliminary indications are that none of the patients receiving Bucillamine in the trial have to date been hospitalised for COVID-19 or have died from COVID-19.
The present invention, in another embodiment, relates to a use of a pharmaceutical composition including bucillamine or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers, diluents and excipients for the treatment of an infectious disease. In another aspect, the infectious disease is influenza. In another aspect, the infectious disease is coronavirus disease.
References
1 Muthuri SG, Venkatesan S, Myles PR et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data Lancet Respir Med. 2014 May;2(5):395-404. doi: 10.1016/S2213-2600(14)70041 -4.
2 Duwe S. Influenza viruses - antiviral therapy and resistance. GMS Infect Dis. 2017; 5: Doc04.
3 Zhang RH, Li CH, Wang CL et al. N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury. Int Immunopharmacol. 2014 Sep;22(1):1-8. doi: 10.1016/j.intimp.2014.06.013.
4 Ungheri D, Pisani C, Sanson G et al. Protective effect of n-acetylcysteine in a model of influenza infection in mice. Int J Immunopathol Pharmacol. 2000 Sep- Dec; 13(3): 123-128. 5 De Flora S, Grassi C, and Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J 1997; 10: 1535-1541 DOI: 10.1183/09031936.97.10071535
6 Poole LB. The Basics of Thiols and Cysteines in Redox Biology and Chemistry. Free Radio Biol Med. 2015 Mar; 0: 148-157. doi: 10.1016/j.freeradbiomed.2014.11.013.
7 Mata M, Morcillo E, Gimeno C, Cortijo J. N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochem Pharmacol. 2011 Sep 1 ;82(5):548-55. doi: 10.1016/j. bcp.2011.05.014.
8. Horowitz LD. Bucillamine: a potent thiol donor with multiple clinical applications. Cardiovasc Drug Rev. 2003 Summer;21(2):77-90.
9. Sagawa A, Fujisaku A, Ohnishi K et al. A multicentre trial of bucillamine in the treatment of early rheumatoid arthritis (SNOW study). Mod Rheumatol. 2011 Jun;21 (3):251-7. doi: 10.1007/s10165-010-0385-4.

Claims

We claim:
1. A method for the treatment or prevention of an infectious disease in a mammal comprising administering a therapeutically effective amount of bucillamine or a pharmaceutically acceptable salt or solvate thereof to a mammal in need thereof.
2. The method of claim 1, wherein the infectious disease is coronavirus disease 2019.
3. The method of claim 2, wherein the therapeutically effective amount is 100 mg.
4. The method of claim 2, wherein the therapeutically effective amount is 200 mg.
5. The method of claim 2, wherein the therapeutically effective amount is in the range of about 100 mg to about 200 mg.
6. The method of claim 2, wherein the therapeutically effective amount is in the range of about 10 mg to about 50 mg.
7. The method of claim 2, wherein the therapeutically effective amount is 300 mg per day.
8 The method of claim 2, wherein the therapeutically effective amount is 600 mg per day.
9. The method of claim 1 , wherein the infectious disease is influenza.
10. The method of claim 9, wherein the therapeutically effective amount is 100 mg.
11. The method of claim 9, wherein the therapeutically effective amount is 200 mg.
12. The method of claim 9, wherein the therapeutically effective amount is in the range of about 100 mg to about 200 mg.
13. The method of claim 9, wherein the therapeutically effective amount is in the range of about 10 mg to about 50 mg.
14. The method of claim 9, wherein the therapeutically effective amount is 300 mg per day.
15 The method of claim 9, wherein the therapeutically effective amount is 600 mg per day.
16. Use of a therapeutically effective amount of bucillamine or a pharmaceutically acceptable salt or solvate thereof for treating or preventing an infectious disease in a mammal.
17. The use of claim 12, wherein the infectious disease is coronavirus disease 2019.
18. The use of claim 17, wherein the infectious disease is coronavirus disease 2019.
19. The use of claim 17, wherein the therapeutically effective amount is 100 mg.
20. The use of claim 17, wherein the therapeutically effective amount is 200 mg.
21. The use of claim 17, wherein the therapeutically effective amount is in the range of about 100 mg to about 200 mg.
22. The use of claim 17, wherein the therapeutically effective amount is in the range of about 10 mg to about 50 mg.
23. The use of claim 12, wherein the infectious disease is influenza.
24. The use of claim 16, wherein the therapeutically effective amount is 100 mg.
25. The use of claim 16, wherein the therapeutically effective amount is 200 mg.
26. The use of claim 16, wherein the therapeutically effective amount is in the range of about 100 mg to about 200 mg.
27. The use of claim 16, wherein the therapeutically effective amount is in the range of about 10 mg to about 50 mg.
28. The use of claim 16, wherein the therapeutically effective amount is 300 mg per day.
29. The use of claim 16, wherein the therapeutically effective amount is 600 mg per day.
30. The use of claim 16 for preventing or reducing acute lung injury during an infection.
PCT/CA2021/050350 2020-03-19 2021-03-16 Use of bucillamine in the treatment of infectious diseases WO2021184115A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US17/912,597 US20230172884A1 (en) 2020-03-19 2021-03-16 Use of bucillamine in the treatment of infectious diseases
CA3172170A CA3172170A1 (en) 2020-03-19 2021-03-16 Use of bucillamine in the treatment of infectious diseases
JP2022556099A JP2023518430A (en) 2020-03-19 2021-03-16 Use of bucillamine in the treatment of infections
KR1020227036230A KR20230015320A (en) 2020-03-19 2021-03-16 Use of Busillamine in the Treatment of Infectious Diseases
EP21772039.0A EP4121035A4 (en) 2020-03-19 2021-03-16 Use of bucillamine in the treatment of infectious diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062991996P 2020-03-19 2020-03-19
US62/991,996 2020-03-19

Publications (1)

Publication Number Publication Date
WO2021184115A1 true WO2021184115A1 (en) 2021-09-23

Family

ID=77767915

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2021/050350 WO2021184115A1 (en) 2020-03-19 2021-03-16 Use of bucillamine in the treatment of infectious diseases

Country Status (6)

Country Link
US (1) US20230172884A1 (en)
EP (1) EP4121035A4 (en)
JP (1) JP2023518430A (en)
KR (1) KR20230015320A (en)
CA (1) CA3172170A1 (en)
WO (1) WO2021184115A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014953A1 (en) * 2008-08-01 2010-02-04 The Regents Of The University Of Colorado, A Body Corporate Prolonged administration of a dithiol anti-oxidant protects against ventricular remodeling
CA2781314A1 (en) * 2010-01-28 2011-08-04 The Johns Hopkins University Compositions and methods for reversing corticosteroid resistance or treating respiratory infections
WO2011147753A1 (en) * 2010-05-26 2011-12-01 Katholieke Universiteit Leuven, K.U.Leuven R&D Antiviral activity of novel bicyclic heterocycles
CA3017797A1 (en) * 2016-03-17 2017-09-21 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
US20190142792A1 (en) * 2010-03-06 2019-05-16 Cacao Bio-Technologies, Llc Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025393A (en) * 1995-09-25 2000-02-15 Santen Pharmaceutical Co., Ltd. Method for treatment of inflammatory intestinal diseases
CA2888647A1 (en) * 2012-11-20 2014-05-30 Revive Therapeutics Inc. The use of bucillamine in the treatment of gout

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014953A1 (en) * 2008-08-01 2010-02-04 The Regents Of The University Of Colorado, A Body Corporate Prolonged administration of a dithiol anti-oxidant protects against ventricular remodeling
CA2781314A1 (en) * 2010-01-28 2011-08-04 The Johns Hopkins University Compositions and methods for reversing corticosteroid resistance or treating respiratory infections
US20190142792A1 (en) * 2010-03-06 2019-05-16 Cacao Bio-Technologies, Llc Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts
WO2011147753A1 (en) * 2010-05-26 2011-12-01 Katholieke Universiteit Leuven, K.U.Leuven R&D Antiviral activity of novel bicyclic heterocycles
CA3017797A1 (en) * 2016-03-17 2017-09-21 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
D UNGHERI, C PISANI, G SANSON, A BERTANI, G SCHIOPPACASSI, R DELGADO, M SIRONI, P GHEZZI: "Protective effect of n-acetylcysteine in a model of influenza infection in mice", INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, vol. 13, no. 3, 2000, GB , pages 123 - 128, XP009540174, ISSN: 0394-6320 *
FLORA DE S., GRASSI C., CARATI L.: "ATTENUATION OF INFLUENZA-LIKE SYMPTOMATOLOGY AND IMPROVEMENT OF CELL-MEDIATED IMMUNITY WITH LONG-TERM N-ACETYLCYSTEINE TREATMENT.", EUROPEAN RESPIRATORY JOURNAL, EUROPEAN RESPIRATORY SOCIETY, GB, vol. 10., 1 July 1997 (1997-07-01), GB , pages 1535 - 1541., XP002912424, ISSN: 0903-1936, DOI: 10.1183/09031936.97.10071535 *
LAWRENCE D. HORWITZ: "Bucillamine: A Potent Thiol Donor with Multiple Clinical Applications", CARDIOVASCULAR DRUG REVIEWS, NEVA PRESS, BRANFORD, CT, US, vol. 21, no. 2, 1 June 2003 (2003-06-01), US , pages 77 - 90, XP055256998, ISSN: 0897-5957, DOI: 10.1111/j.1527-3466.2003.tb00107.x *
MATA MANUEL, MORCILLO ESTEBAN, GIMENO CONCEPCION, CORTIJO JULIO: "N-acetyl-l-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV)", BIOCHEMICAL PHARMACOLOGY, ELSEVIER, US, vol. 82, no. 5, 1 September 2011 (2011-09-01), US , pages 548 - 555, XP055858776, ISSN: 0006-2952, DOI: 10.1016/j.bcp.2011.05.014 *
See also references of EP4121035A4 *

Also Published As

Publication number Publication date
JP2023518430A (en) 2023-05-01
EP4121035A4 (en) 2024-04-24
CA3172170A1 (en) 2021-09-23
KR20230015320A (en) 2023-01-31
EP4121035A1 (en) 2023-01-25
US20230172884A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
CN109476701B (en) Composition for protecting cells comprising cyclamic acid-proline as active ingredient
EP1484059B1 (en) Antiviral compositions comprising phenylacetic acid derivatives
KR20170102013A (en) Compositions and methods for inhibiting fungal infections
WO2009015560A1 (en) Use of allylcysteine or its analogs and pharmaceutical composition threrof
US6579891B1 (en) Agent and method for prevention and treatment of cancer in animals
JP2006511538A (en) Use of a combination comprising a non-nucleoside reverse transcriptase inhibitor (NNRTI) and a cytochrome P450 inhibitor such as a protease inhibitor
JP2022019937A (en) Composition for preventing or treating chronic or acute virus infection and/or sepsis in humans or animals
OA12862A (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone.
WO2021184115A1 (en) Use of bucillamine in the treatment of infectious diseases
US9149514B2 (en) Composition and method for treating papilloma virus and equine sarcoids
US20170258746A1 (en) Acetic acid/thymol compositions and their use in the treatment of onychomycosis
JPS60104019A (en) Drug for viral disease
RU2721409C1 (en) Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for treating blood cancer
US20060287364A1 (en) Methods of prevention of infection with HIV/AIDS, venereal disease and influenza
JP2002265354A (en) Anti-helicobacter pylori agent composition
US20080145409A1 (en) Composition for the treatment and prevention of peptic ulcer
KR102387565B1 (en) Pharmaceutical composition for preventing or treating cancer comprising streptonigrin and anticancer agent
EP4159214A1 (en) Composition for treating, improving, and/or preventing progression of bovine papillomatosis caused by bovine papillomavirus
KR20180015594A (en) Composition comprising squalene for enhancement of muscle function and prevention of muscle damage
CA3236666A1 (en) Use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] to ameliorate proteasome inhibitor resistance
JPS58154510A (en) Use of alpha,alpha-dialkyladamantylamine for treatment of measles
JP2021095358A (en) AGR2 expression promoter
JP2876224B2 (en) New whitening agent
JP4733348B2 (en) Combination preparation of sodium-hydrogen exchange inhibitor kalipolide and ACE inhibitor for prevention of heart failure, other age-related organ dysfunctions and age-related disorders, and for extending lifespan
JP2023540466A (en) Antiviral composition and its use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21772039

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022556099

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3172170

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021772039

Country of ref document: EP

Effective date: 20221019